The nation of Zimbabwe has declined a major US health deal valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's demand for confidential information.
This rejection came to light after a government memo from December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government representative has since clarified that the US was seeking biological samples for scientific study and profit but was not willing to share the benefits from future medical innovations.
"We must now begin the difficult and regrettable process of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated over $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for continued dialogue to find a agreement agreeable to all parties so the nation's vital HIV programme can be sustained.
Broader Context
This development comes after a comparable case in Kenya, where a high court halted a related health funding agreement after legal challenges were raised about the safety of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had administered assistance for the US government, but Trump stated its spending was "wasteful" and his government was seeking direct bilateral agreements to boost openness and responsibility.
According to reports, Sixteen African countries have to date signed similar health pacts, representing over $18.3bn in committed funds.
Details of the Declined Deal
The funds for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment through US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, without any equivalent guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"In essence, our country would provide the basic resources for medical research with no assurance that the final treatments would be available to our people if a future pandemic emerge."
National Interest and Global Health
He also said that the American exit from the global health body and its pursuit of one-on-one deals were disrupting frameworks previously established via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential pandemics.
"This system is designed to guarantee that when a country provides its information, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to create them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to ongoing dialogue with our American counterparts on how future co-operation might be structured in a way that respects the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body said it acknowledged the official position, but suggested that negotiations need to persist considering much of the nation's Aids initiatives depended on foreign aid.
"If specific concerns exist, such as those involving data governance or implementation frameworks, these can frequently be addressed through detailed discussion and mutually agreed protections," it commented.
The situation emphasises the ongoing challenges between accepting vital international aid and protecting national sovereignty in an increasingly interconnected world.